Naturally occurring K vitamins inhibit pancreatic cancer cell survival through a caspase-dependent pathway

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 4, 2010, Pages 738-744

  Showalter, Shayna L ^a   Wang, Ziqiu ^b   Costantino, Christina L ^a   Witkiewicz, Agnieszka K ^b   Yeo, Charles J ^a   Brody, Jonathan R ^a   Carr, Brian I ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Pancreatic cancer; Pancreatic ductal adenocarcinoma; Vitamin K

Indexed keywords

CASPASE; CASPASE INHIBITOR; FARNOQUINONE; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHYTOMENADIONE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CELL SURVIVAL; DRUG MECHANISM; DRUG SAFETY; HUMAN; HUMAN CELL; IC 50; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 77950104094     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.06085.x     Document Type: Article

References (32)

1. Garcea G, Dennison AR, Pattenden CJ et al. Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. JOP 2008 9 : 99 132.
2. Smeenk HG, Tran TC, Erdmann J et al. Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist? Langenbecks Arch. Surg. 2005 390 : 94 103.
3. Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 2004 350 : 1200 1210.
4. Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007 297 : 267 277.
5. Regine WF, Winter KA, Abrams RA et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008 299 : 1019 1026.
6. Mancuso A, Calabro F, Sternberg CN. Current therapies and advances in the treatment of pancreatic cancer. Crit. Rev. Oncol. Hematol. 2006 58 : 231 241.
7. Burris H 3rd., Rocha-Lima C. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist 2008 13 : 289 298.
8. Furie B, Furie BC. The molecular basis of blood coagulation. Cell 1988 53 : 505 518.
9. Suttie JW. Mechanism of action of vitamin K: synthesis of gamma-carboxyglutamic acid. CRC Crit. Rev. Biochem. 1980 8 : 191 223.
10. Price PA. Role of vitamin-K-dependent proteins in bone metabolism. Annu. Rev. Nutr. 1988 8 : 565 583.
11. Benzakour O, Kanthou C. The anticoagulant factor, protein S, is produced by cultured human vascular smooth muscle cells and its expression is up-regulated by thrombin. Blood 2000 95 : 2008 2014.
12. Shanahan CM, Proudfoot D, Farzaneh-Far A et al. The role of Gla proteins in vascular calcification. Crit. Rev. Eukaryot. Gene Expr. 1998 8 : 357 375.
13. Tsaioun KI. Vitamin K-dependent proteins in the developing and aging nervous system. Nutr. Rev. 1999 57 : 231 240.
14. Vermeer C, Schurgers LJ. A comprehensive review of vitamin K and vitamin K antagonists. Hematol. Oncol. Clin. North Am. 2000 14 : 339 353.
15. Mizuta T, Ozaki I. Hepatocellular carcinoma and vitamin K. Vitam. Horm. 2008 78 : 435 442.
16. Matsumoto K, Okano J, Nagahara T et al. Apoptosis of liver cancer cells by vitamin K2 and enhancement by MEK inhibition. Int. J. Oncol. 2006 29 : 1501 1508.
17. Nishikawa Y, Carr BI, Wang M et al. Growth inhibition of hepatoma cells induced by vitamin K and its analogs. J. Biol. Chem. 1995 270 : 28304 28310.
18. Osada S, Carr BI. Critical role of extracellular signal-regulated kinase (ERK) phosphorylation in novel vitamin K analog-induced cell death. Jpn J. Cancer Res. 2000 91 : 1250 1257.
19. Wang Z, Wang M, Finn F, Carr BI. The growth inhibitory effects of vitamins K and their actions on gene expression. Hepatology 1995 22 : 876 882.
20. Ozaki I, Zhang H, Mizuta T et al. Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibition of nuclear factor kappaB activation. Clin. Cancer Res. 2007 13 : 2236 2245.
21. Hitomi M, Yokoyama F, Kita Y et al. Antitumor effects of vitamins K1, K2 and K3 on hepatocellular carcinoma in vitro and in vivo. Int. J. Oncol. 2005 26 : 713 720.
22. Yoshiji H, Kuriyama S, Noguchi R et al. Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression. J. Hepatol. 2005 42 : 687 693.
23. Otsuka M, Kato N, Shao RX et al. Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. Hepatology 2004 40 : 243 251.
24. Kanamori T, Shimizu M, Okuno M et al. Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma cells. Cancer Sci. 2007 98 : 431 437.
25. Jones S, Zhang X, Parsons DW et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008 321 : 1801 1806.
26. Saxena SP, Fan T, Li M et al. A novel role for vitamin K1 in a tyrosine phosphorylation cascade during chick embryogenesis. J. Clin. Invest. 1997 99 : 602 607.
27. Osada S, Saji S, Osada K. Critical role of extracellular signal-regulated kinase phosphorylation on menadione (vitamin K3) induced growth inhibition. Cancer 2001 91 : 1156 1165.
28. Osada S, Sakashita F, Hosono Y et al. Extracellular signal-regulated kinase phosphorylation due to menadione-induced arylation mediates growth inhibition of pancreas cancer cells. Cancer Chemother. Pharmacol. 2008 62 : 315 320.
29. Osada S, Tomita H, Tanaka Y et al. The utility of vitamin K3 (menadione) against pancreatic cancer. Anticancer Res. 2008 28 (1A 45 50.
30. Brody JR, Hucl T, Gallmeier E et al. Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine therapy. Cancer Res. 2006 66 : 9369 9373.
31. Orimo H, Shiraki M, Tomita A et al. Effects of menatetrenone on the bone and calcium metabolism in osteoporosis: A double-blind placebo-controlled study. J Bone Miner Metab 1998 16 : 106 112.
32. Mizuta T, Ozaki I, Eguchi Y et al. The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study. Cancer 2006 106 : 867 872.